Four manuscripts that provide information on different aspects of thoracic oncology are highlighted in the February issue of JTO. The first manuscript, Racial diversity of actionable mutations in non-small cell lung cancer, by Bollig-Fischer et al. provides information on racial differences in actionable mutations in NSCLC in the US, and is accompanied by an excellent editorial from Dr Tetsuya Mitsudomi. The second manuscript by Um et al, addresses the important issue of mediastinial nodal staging for the work-up of NSCLC - Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-small Cell Lung Cancer. Um et al. Weiss et al provide critical information on thymoma in The Impact of Thymoma Histotype on Prognosis in a Worldwide Database. Weis et al. Finally, Gainor et al present a series of patients with ALK rearranged NSCLC who developed leptomeningeal disease on crizotinib and responded to alectinib- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib. Gainor et al.
Alex A. Adjei, MD, PhD, Editor-in-Chief